Feasibility study for multicenter randomized controlled phase III clinical trial of cisplatin + irinotecan therapy and cisplatin + irinotecan + Krestin [polysaccharide K] therapy for extensive-stage disease (ED) small cell lung cancer
Phase of Trial: Phase III
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Polysaccharide K (Primary) ; Cisplatin; Irinotecan
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Acronyms RNCLC
- 17 Jul 2008 Status changed from initiated to recruiting as reported by ClinicalTrials.gov.
- 30 Oct 2007 New trial record.